The United States of America as Represented by the Department of Health

The United States of America, as Represented by the Secretary, Department of Health and Human Services

The United States of America as Represented by the Secretary of

The United States of America

David Fitzgerald

Ira H Pastan

Ulrich Brinkmann

Bernard Moss

Tamio Mizukami

Mark C Willingham

Edward A Berger

Thomas R Fuerst

Lee Pai

Satoshi Nagata

Masanori Onda

Byungkook Lee

Vijay K Chaudhary

Robert Kreitman

Vijay Kumar Chaudhary

John Weldon

The invention provides mutatedexotoxins (PE) that have reduced immunogenicity compared to PEs containing the native sequence. The PEs of the invention have one or more individual mutations of positions of the native sequence of PE that reduce antibody binding to one or more PE epitopes. Nucleic acids encoding the mutated PEs, chimeric molecules comprising them, compositions comprising the chimeric molecules and methods of using them, are also provided.

[object Object]

This invention provides for recombinant single chain antibodies capable of specifically binding to a Lewis.sup.Y -related carbohydrate antigen and fusion proteins comprising these antibodies. More particularly, the invention provides for single chain Fv regions of the monoclonal antibody B3. The invention also provides for a method of improving the binding affinity of antibodies lacking a serine at position 95 of the V.sub.H region that involves mutating position 95 to a serine.

Single chain B3 antibody fusion proteins and their uses

A chimeric gene directing the synthesis of hybrid recombinant fusion protein in a suitable expression vector has been constructed. The fusion protein possesses the property of selective cytotoxicity against specific virus-infected cells. A CD4(178)-PE40 hybrid fusion protein has been made for selectively killing HIV-infected cells.

Cytotoxic agent against specific virus infection

Growing community of inventors

Rockville, MD, United States of America

David Fitzgerald